Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

BACKGROUND LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK. A Phase 1 dose escalation, 200 mg twice daily (BID) of LY3023414 was the determined recommended phase 2 dose (RP2D). We report the antitumor activity and safety of LY3023414 monotherapy in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zauderer, Marjorie G., Alley, Evan W., Bendell, Johanna, Capelletto, Enrica, Bauer, Todd M., Callies, Sophie, Szpurka, Anna M., Kang, Suhyun, Willard, Melinda D., Wacheck, Volker, Varghese, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280020/
https://www.ncbi.nlm.nih.gov/pubmed/33660194
http://dx.doi.org/10.1007/s10637-021-01086-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280020/
https://www.ncbi.nlm.nih.gov/pubmed/33660194
http://dx.doi.org/10.1007/s10637-021-01086-6

Ejemplares similares